The effectiveness removes the last regulatory hurdle for the offering. Monitor for pricing announcement (typically 1-2 days post-effectiveness) and Nasdaq uplisting approval. The stock may trade with elevated volatility as the offering price and dilution terms are finalized.
Price Chart
Executive Summary
Eloxx Pharmaceuticals' S-1 registration statement (File No. 333-295651) became effective on June 8, 2026, clearing the way for the company to proceed with its public offering of common stock and pre-funded warrants. The offering is expected to raise approximately $54.2 million in net proceeds to fund Phase 2b and Phase 2 trials of exaluren for Alport syndrome and ADPKD, contingent upon Nasdaq uplisting approval. This is a critical capital event for a company currently trading on the OTC market with a going concern qualification.
Key Facts
- S-1 registration (File No. 333-295651) declared effective by SEC on June 8, 2026.
- Offering includes 2,730,000 shares of common stock and pre-funded warrants to purchase up to 2,770,000 shares.
- Estimated net proceeds of approximately $54.2 million.
- Proceeds intended to fund Phase 2b trial of exaluren in Alport syndrome (topline data mid-2027) and Phase 2 trial in ADPKD (topline data mid-2028).
- Offering is contingent upon Nasdaq uplisting approval; company currently trades on OTC Pink Limited Market.
- Company has a going concern qualification and was previously delisted from Nasdaq in 2023.
Financial Impact
Approximately $54.2 million in net proceeds from the offering.
Risk Factors
- Dilution from the issuance of up to 5.5 million shares (including pre-funded warrants).
- Nasdaq uplisting approval is not guaranteed; failure would likely scuttle the offering.
- Going concern qualification remains unless the offering closes successfully.
- Clinical trial risk: exaluren Phase 2b data not expected until mid-2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001918 |
| Document: 9999999995-26-001918-index.html | 9999999995-26-001918 |
| Document: 9999999995-26-001918.txt | 9999999995-26-001918 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | 8-K | $13.12 | awaiting T+20 | — | $13.17 (+0.38%) |
Sep 21, 2026 5w ago | EFFECT | $17.19 $12.50 | ▼ −27.28% | ▼ −26.38% | $13.17 (−23.39%) |
Sep 11, 2026 6w ago | S-1 | $16.30 | awaiting T+20 | — | $13.17 (−19.20%) |
Jun 9, 2026 19w ago | EFFECT | $11.01 $10.95 | ▼ −0.55% | ▼ −1.99% | $13.17 (+19.62%) |
Jun 4, 2026 20w ago | S-1/A | $6.20 | awaiting T+20 | — | $13.17 (+112.42%) |
Jun 1, 2026 20w ago | S-1/A | $1.51 | awaiting T+20 | — | $13.17 (+772.19%) |
Jun 1, 2026 21w ago | 8-K | $4.07 $13.88 | ▲ +241.03% | ▲ +242.33% | $13.17 (+223.59%) |
May 7, 2026 24w ago | S-1 | $1.43 | awaiting T+20 | — | $13.17 (+820.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers